Moleculin Biotech Inc.

0.86
-0.14 (-14.00%)
At close: Feb 06, 2025, 2:20 PM
undefined%
Bid 0.86
Market Cap 2.91M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -12.04
PE Ratio (ttm) -0.07
Forward PE n/a
Analyst Buy
Ask 0.88
Volume 1,157,873
Avg. Volume (20D) 64,485
Open 0.94
Previous Close 1.00
Day's Range 0.84 - 0.94
52-Week Range 0.40 - 6.24
Beta undefined

About MBRX

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 18
Stock Exchange NASDAQ
Ticker Symbol MBRX

Analyst Forecast

According to 2 analyst ratings, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 2690.37% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago
+14.72%
Moleculin Biotech shares are trading higher after ... Unlock content with Pro Subscription
2 months ago
+23.11%
Moleculin Biotech shares are trading higher after the company announced it amended the clinical trial protocol with the FDA for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine for the treatment of AML patients who are refractory to or relapsed after induction therapy.